The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Development of PI3K inhibitors: lessons learned from early clinical trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A. Y., Sougnez, C., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,179
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Self-citationChoo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Self-citationHess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Self-citationAKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Tenbaum, S. P., Ordóñez-Morán, P., Puig, I., Chicote, I., Arqués, O., Landolfi, S., Fernández, Y., Herance, J. R., Gispert, J. D., Mendizabal, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2772 · Cited by 386
Self-citationPKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival
Bozulic, L., Surucu, B., Hynx, D., & Hemmings, B. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.024 · Cited by 386
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Self-citationDetection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 309
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303
Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 257
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
Busaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 190
Mothe‐Satney, I., Yang, D., Fadden, P., Haystead, T., & Lawrence, J. C. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3558-3567.2000 · Cited by 187
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165
Roper, J., Richardson, M. P., Wang, W. V., Richard, L. G., Chen, W., Coffee, E. M., Sinnamon, M. J., Lee, L., Chen, P., Bronson, R. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025132 · Cited by 147
Dienstmann, R., Braña, I., Rodon, J. A., & Tabernero, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0163 · Cited by 144
Self-citationGene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review)
Libra, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1312 · Cited by 142
Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A. R., Moasser, M. M., Weiss, W. A., Shokat, K. M., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 134
Cutsem, E. V., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 134
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 120
Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
Hanrahan, A. J., Schultz, N. D., Westfal, M. L., Sakr, R. A., Giri, D. D., Scarperi, S., Janikariman, M., Olvera, N., Stevens, E. V., She, Q., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0170 · Cited by 118
Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
Edgar, K. A., Wallin, J. J., Berry, M., Lee, L. B., Prior, W. W., Sampath, D., Friedman, L. S., & Belvin, M. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2525 · Cited by 117
Ma, W. W., Jacene, H. A., Song, D., Vilardell, F., Messersmith, W. A., Laheru, D. A., Wahl, R. L., Endres, C., Jimeno, A., Pomper, M. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8383 · Cited by 117
Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109
Self-citationINPP4B: the New Kid on the PI3K Block
Agoulnik, I. U., Hodgson, M. C., Bowden, W. A., & Ittmann, M. (2011) · Oncotarget · doi:10.18632/oncotarget.260 · Cited by 106
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
Braña, I., & Siu, L. L. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-161 · Cited by 96
Awasthi, N., Yen, P. L., Schwarz, M. A., & Schwarz, R. E. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23405 · Cited by 93
Wallin, J. J., Guan, J., Prior, W. W., Lee, L. B., Berry, L., Belmont, L. D., Koeppen, H., Belvin, M. P., Friedman, L. S., & Sampath, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2088 · Cited by 88
Edelman, G. M., Bedell, C., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Scheffold, C., Nguyen, L. T., Laird, A., Baselga, J. M., & Rodon, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3004 · Cited by 77
Self-citationWagner, A. J., Bendell, J. C., Dolly, S. O., Morgan, J. A., Ware, J. A., Fredrickson, J. O., Mazina, K. E., Lauchle, J., Burris, H. A., & Bono, J. S. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3020 · Cited by 73
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 68
Self-citationPI3K: A potential therapeutic target for cancer
Chen, Y., Wang, B., & Xiao, Y. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.23038 · Cited by 62
Juric, D., Rodon, J. A., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J. C., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-ct-01 · Cited by 62
Self-citationHER2が増幅されPI3K3CAが変異した乳癌細胞におけるPI3K/mTor二重阻害剤NVP‐BEZ235による特異的アポトーシス誘発
Saskia, M. B., Irmgard, H., Christian, S., et al. (2009) · Cited by 60
McKinley, E. T., Bugaj, J. E., Zhao, P., Guleryuz, S., Mantis, C., Gokhale, P. C., Wild, R., & Manning, H. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2274 · Cited by 52
Braña, I., LoRusso, P. M., Baselga, J. M., Heath, E. I., Patnaik, A., Gendreau, S., Laird, A., & Papadopoulos, K. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3030 · Cited by 51
Tan, D. S.-W., Dumez, H., Olmos, D., Sandhu, S. K., Hoeben, A., Stephens, A. W., Poondru, S., Gedrich, R. W., Kaye, S. B., & Schöffski, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3006 · Cited by 50
Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C. D., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J., Gonzalez, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3003 · Cited by 50
Tenbaum, S. P., Ordóñez‐Morán, P., Puig, I., Chicote, I., Arqués, O., Vivancos, A. P., Baselga, J. M., Tabernero, J. M., Munoz, A., & Pálmer, H. G. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71330-8 · Cited by 50
Self-citationLoRusso, P. M., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Jones, C. A., Belvin, M. P., Musib, L. C., de Crespigny, A. J., McKenzie, M., Gates, M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2566 · Cited by 48
Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
Juric, D., & Baselga, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6390 · Cited by 43
Furman, R. R., Byrd, J. C., Flinn, I. W., Coutre, S. E., Benson, D. M., Brown, J. R., Kahl, B. S., Wagner‐Johnston, N. D., Giese, N. A., & Yu, A. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3032 · Cited by 43
Khan, K. H., Yan, L., Mezynski, J., Patnaik, A., Moreno, V., Papadopoulos, K. P., Garrett, C. R., Ong, M., Shannon, K. A., Morosky, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13599 · Cited by 36
Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012) · PubMed · Cited by 35
Dissecting “PI3Kness”: The Complexity of Personalized Therapy for Ovarian Cancer
Bast, R. C., & Mills, G. B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0323 · Cited by 34
Morrow, C. J., Gray, A., & Dive, C. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.096 · Cited by 31
Williams, R. R., Baker, A. F., Ihle, N. T., Winkler, A. R., Kirkpatrick, L., & Powis, G. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0190-0 · Cited by 28
Mayer, I., Abramson, V. G., Balko, J. M., Isakoff, S., Kuba, M. G., Sanders, M., Forero, A., Yap, J. T., den Abbeele, A. D. V., Li, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.510 · Cited by 23
Bedard, P. L., Tabernero, J. M., Kurzrock, R., Britten, C. D., Stathis, A., Pérez-García, J. M., Zubel, A., Le, N. T., Carter, K., Bellew, K. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3003 · Cited by 23
Self-citationClinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
Arteaga, C. L. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_54 · Cited by 20
Speranza, G., Kinders, R. J., Khin, S. A., Weil, M. K., Do, K. T., Horneffer, Y. R., Juwara, L., Allen, D. E., Williams, P. M., Lih, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3529 · Cited by 19
RAF/MEK Dependence of KRAS-Mutant Pancreatic Ductal Adenocarcinomas
Hanrahan, A. J., & Solit, D. B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0308 · Cited by 12
Saura, C., Jones, S. F., Mateo, J., Hollebecque, A., Cleary, J. M., Perez, D. R., Zhu, J., Musib, L. C., Patel, P. H., Cervantes, A. M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3021 · Cited by 6
Self-citation
Cited by
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-02-12
- Volume
- 10
- Issue
- 3
- Pages
- 143-153
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2038444072
- Cited by
- 766
- References
- 95
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.